Ceritinib Treatment for Carcinomatous Meningitis with a Secondary Mutation at I1171T in Anaplastic Lymphoma Kinase

Internal Medicine ◽

10.2169/internalmedicine.0397-17 ◽

2018 ◽

Vol 57 (21) ◽

pp. 3153-3155 ◽

Author(s):

Hironori Ashinuma ◽

Masato Shingyoji ◽

Yuzo Hasegawa ◽

Sana Yokoi ◽

Yasushi Yoshida

Keyword(s):

Anaplastic Lymphoma Kinase ◽

Carcinomatous Meningitis ◽

Secondary Mutation ◽

Anaplastic Lymphoma

Download Full-text

A Low Crizotinib Concentration in the Cerebrospinal Fluid Causes Ineffective Treatment of Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer with Carcinomatous Meningitis

Internal Medicine ◽

10.2169/internalmedicine.1072-18 ◽

2019 ◽

Vol 58 (5) ◽

pp. 703-705 ◽

Author(s):

Tamio Okimoto ◽

Yukari Tsubata ◽

Takamasa Hotta ◽

Megumi Hamaguchi ◽

Mika Nakao ◽

...

Keyword(s):

Lung Cancer ◽

Cerebrospinal Fluid ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Anaplastic Lymphoma Kinase ◽

Carcinomatous Meningitis ◽

Small Cell Lung ◽

Anaplastic Lymphoma

Download Full-text

Enteral lorlatinib after alectinib as a treatment option in anaplastic lymphoma kinase‐positive non‐small cell lung cancer with triple problems: carcinomatous meningitis, poor performance status, and dysphagia—a case report

Respirology Case Reports ◽

10.1002/rcr2.796 ◽

2021 ◽

Vol 9 (7) ◽

Author(s):

Kota Sasaki ◽

Yusuke Yokota ◽

Toshihito Isojima ◽

Mayumi Fujii ◽

Kengo Hasui ◽

...

Keyword(s):

Lung Cancer ◽

Case Report ◽

Anaplastic Lymphoma Kinase ◽

Performance Status ◽

Poor Performance ◽

Carcinomatous Meningitis ◽

Poor Performance Status ◽

Small Cell Lung ◽

Anaplastic Lymphoma

Download Full-text

Regulated expression of the Anaplastic Lymphoma Kinase (ALK) in cultured rat hepatic stellate cells during transdifferentiation into myofibroblasts

Zeitschrift für Gastroenterologie ◽

10.1055/s-2005-861584 ◽

2005 ◽

Vol 43 (01) ◽

Author(s):

M Antoine ◽

CG Tag ◽

W Wirz ◽

M Mavituna ◽

AM Gressner ◽

...

Keyword(s):

Hepatic Stellate Cells ◽

Anaplastic Lymphoma Kinase ◽

Stellate Cells ◽

Anaplastic Lymphoma ◽

Regulated Expression

Download Full-text

Anaplastic Lymphoma Kinase in Human Cancer

Critical Reviews™ in Oncogenesis ◽

10.1615/critrevoncog.v17.i2.10 ◽

2012 ◽

Vol 17 (2) ◽

pp. 123-143 ◽

Author(s):

Christina Schonherr ◽

Bengt Hallberg ◽

Ruth Palmer

Keyword(s):

Anaplastic Lymphoma Kinase ◽

Human Cancer ◽

Anaplastic Lymphoma

Download Full-text

Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC)

Case Medical Research ◽

10.31525/ct1-nct04009317 ◽

2019 ◽

Author(s):

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Anaplastic Lymphoma Kinase ◽

Line Treatment ◽

Small Cell Lung ◽

Anaplastic Lymphoma ◽

Alk Positive ◽

First Line Treatment

Download Full-text

Faculty Opinions recommendation of Anaplastic lymphoma kinase spares organ growth during nutrient restriction in Drosophila.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.12593957.791402800 ◽

2012 ◽

Author(s):

Savraj Grewal

Keyword(s):

Anaplastic Lymphoma Kinase ◽

Nutrient Restriction ◽

Organ Growth ◽

Anaplastic Lymphoma

Download Full-text

Faculty Opinions recommendation of The anaplastic lymphoma kinase in the pathogenesis of cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.13353985.14725086 ◽

2011 ◽

Author(s):

Ruth Palmer

Keyword(s):

Anaplastic Lymphoma Kinase ◽

Anaplastic Lymphoma

Download Full-text

Faculty Opinions recommendation of Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.12934957.14822055 ◽

2012 ◽

Author(s):

John Proudfoot

Keyword(s):

Drug Design ◽

Anaplastic Lymphoma Kinase ◽

Dual Inhibitor ◽

Structure Based Drug Design ◽

Anaplastic Lymphoma ◽

Mesenchymal Epithelial Transition Factor ◽

Factor C ◽

Mesenchymal Epithelial Transition

Download Full-text

Faculty Opinions recommendation of Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.12934957.14323054 ◽

2011 ◽

Author(s):

John Lowe

Keyword(s):

Drug Design ◽

Anaplastic Lymphoma Kinase ◽

Dual Inhibitor ◽

Structure Based Drug Design ◽

Anaplastic Lymphoma ◽

Mesenchymal Epithelial Transition Factor ◽

Factor C ◽

Mesenchymal Epithelial Transition

Download Full-text

Faculty Opinions recommendation of Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718242031.793491637 ◽

2014 ◽

Author(s):

Jürgen Bajorath

Keyword(s):

Anaplastic Lymphoma Kinase ◽

Selective Inhibitors ◽

Anaplastic Lymphoma

Download Full-text